Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Debt: 2022-2025

Historic Total Debt for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $109.8 million.

  • Centessa Pharmaceuticals' Total Debt rose 45.07% to $109.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.8 million, marking a year-over-year increase of 45.07%. This contributed to the annual value of $108.9 million for FY2024, which is 43.91% up from last year.
  • Centessa Pharmaceuticals' Total Debt amounted to $109.8 million in Q3 2025, which was up 0.25% from $109.5 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Total Debt registered a high of $109.8 million during Q3 2025, and its lowest value of $67.4 million during Q2 2022.
  • For the 3-year period, Centessa Pharmaceuticals' Total Debt averaged around $87.4 million, with its median value being $76.5 million (2024).
  • In the last 5 years, Centessa Pharmaceuticals' Total Debt declined by 4.28% in 2023 and then spiked by 45.07% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Total Debt (Quarterly) stood at $69.8 million in 2022, then grew by 8.45% to $75.7 million in 2023, then soared by 43.91% to $108.9 million in 2024, then skyrocketed by 45.07% to $109.8 million in 2025.
  • Its Total Debt was $109.8 million in Q3 2025, compared to $109.5 million in Q2 2025 and $109.3 million in Q1 2025.